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Abstract
Background: Environmental exposure to organophosphorus pesticides has been characterized in
various populations, but interpretation of these data from a health risk perspective remains an
issue. The current paper proposes biological reference values to help interpret biomonitoring data
related to an exposure to organophosphorus pesticides in children for which measurements of
alkylphosphate metabolites are available.
Methods: Published models describing the kinetics of malathion and chlorpyrifos in humans were
used to determine no-observed effect level – biomarker equivalents for methylphosphates and
ethylphosphates, respectively. These were expressed in the form of cumulative urinary amounts of
alkylphosphates over specified time periods corresponding to an absorbed no-observed effect level
dose (derived from a published human exposure dose) and assuming various plausible exposure
scenarios. Cumulative amounts of methylphosphate and ethylphosphate metabolites measured in
the urine of a group of Quebec children were then compared to the proposed biological reference
values.
Results: From a published no-observed effect level dose for malathion and chlorpyrifos, the model
predicts corresponding oral biological reference values for methylphosphate and ethylphosphate
derivatives of 106 and 52 nmol/kg of body weight, respectively, in 12-h nighttime urine collections,
and dermal biological reference values of 40 and 32 nmol/kg of body weight. Out of the 442
available urine samples, only one presented a methylphosphate excretion exceeding the biological
reference value established on the basis of a dermal exposure scenario and none of the
methylphosphate and ethylphosphate excretion values were above the obtained oral biological
reference values, which reflect the main exposure route in children.
Conclusion:  This study is a first step towards the development of biological guidelines for
organophophorus pesticides using a toxicokinetic modeling approach, which can be used to
provide a health-based interpretation of biomonitoring data in the general population.
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Background
Many studies have been published on the characterization
of occupational exposure to several pesticides [1-7]. In the
specific context of occupational exposure assessment to
organophosphorus (OP) insecticides, toxicokinetic mod-
els have also been developed, which allow reconstruction
of the amounts of an OP absorbed following an exposure
episode in workers starting from cumulative amounts of
urinary metabolites during specified time periods [8-11].
These models were used to predict cumulative urinary
amounts of OP metabolites resulting from an exposure to
a no-observed effect level (NOEL) dose, which were pro-
posed as biological reference values (BRVs) for prevention
in occupational health. Below these reference values,
workers should not experience adverse health effects,
whatever their exposure conditions, since OP toxicity is
essentially of systemic nature. This approach was applied
to different OP insecticides, namely azinphos-methyl [8],
malathion [9], chlorpyrifos [10], and parathion [11].
In Bouchard et al. [7,9], model simulations under a vari-
ety of exposure scenarios showed that the lowest, thus
most conservative, excretion values were obtained from a
dermal exposure scenario with the slowest possible
absorption rate rather than from respiratory or oral expo-
sure scenarios. From these considerations, occupational
BRVs were derived by simulating a dermal OP exposure
such that the total absorbed daily dose corresponds to the
absorbed NOEL. These guidance values were proposed in
the form of total amounts of OP metabolites collected in
urine over conveniently chosen time periods.
With regard to the assessment of environmental exposure
to OPs in children, in agricultural or non-agricultural
communities, several biomonitoring studies have been
conducted [12-29]. However, dose estimates or health
risks related to these environmental exposures, which
mainly occur through the diet [30], were rarely assessed.
Among the rare published studies on this aspect, one can
cite that of Fenske et al. [26] in which dose estimates,
reconstructed from biomarker concentrations using a sim-
ple calculation, were compared to the acceptable daily
intake (ADI) of the World Health Organization (WHO).
Using a simple calculation, Grandjean et al. [31] also
determined the molar concentrations of alkylphosphates
in urine (adjusted for the body weight) corresponding to
an oral reference dose (RfD) for the most toxic pesticides,
as a worst case scenario. The objective of the current study
was to use a toxicokinetic modelling approach to deter-
mine NOEL – biomarker equivalents (NBE) to help pro-
vide a health-based interpretation of biomonitoring data
from a previous study [22] on OP pesticide exposure
assessment in children of a suburban area of the Province
of Quebec, Canada.
Methods
The proposed approach relies on the use of toxicokinetic
models to simulate the amounts of alkylphosphate
metabolites (APs), methyl and ethyl phosphates (MPs
and EPs, respectively), excreted in urine over given time-
periods that result from an absorbed NOEL dose under
various hypothetical OP environmental exposures that
may occur in children. These urinary amounts, defined as
NOEL-biomarker equivalents (NBEs), were taken as refer-
ence values to which urinary biomarker measurements
can be compared.
More specifically, in the present work, the MP and EP bio-
logical monitoring data reported by Valcke et al. [22] for
each child and each void were expressed in cumulative
amounts in nighttime urine collections per unit of body
weight (BW) and compared to the different NBEs pro-
posed for these OP metabolites. Briefly, a total of 442
complete first-morning urine voids were collected in chil-
dren aged 3–7 during spring and summer, and MP and EP
metabolites were measured in each sample. This sample
was considered to represent approximately a 12-h urine
collection assuming that the children urinated at bedtime,
circa 7 pm, and woke up around 7 am.
For the determination of NBEs for MP and EP metabo-
lites, the models published by Bouchard et al. [9,10] for
malathion and chlorpyrifos (CPF) were respectively used.
Assuming that the children urinated before bedtime
around 7 pm and provided their urine sample around 7
am the following day, the models were run in order to
simulate a 12-h nighttime cumulative urinary excretion,
from 7 pm to 7 am, following three different daily OP
exposure scenarios to NOEL absorbed doses. As was done
in Bouchard et al. [9,10], these NOEL absorbed doses
were derived from published human oral NOEL exposure
doses for the inhibition of red-blood-cell acetylcho-
linesterase (RBC-AChE) activity of 16 mg/day (equivalent
to 0.2 mg/kg BW-day) for malathion [32] and 0.1 mg/kg
BW-day for CPF (Coulston et al., 1972, Institute of exper-
imental pathology and toxicology, Albany Medical col-
lege). Simulations were thus conducted such that the total
absorbed daily dose corresponded to the absorbed NOEL
dose. The absorbed NOEL doses for malathion and chlo-
rpyrifos were obtained by multiplying the published oral
NOEL exposure doses by the absorption fraction deter-
mined in Bouchard et al. [9,10]. Corresponding cumula-
tive amounts of urinary MP and EP biomarkers excreted
during the 12-h nighttime period were then taken as
NBEs.
Two oral exposure scenarios were used, since exposure
was mainly attributed to OP residues in food [16,22,30],
along with a dermal exposure scenario, which although
maybe less realistic, has previously been shown to gener-Environmental Health 2009, 8:5 http://www.ehjournal.net/content/8/1/5
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ate more conservative (lower) reference values [9,10,33].
The three exposure scenarios considered are as follows: 1)
a bolus oral exposure at dinner (6 p.m.) such that the total
daily absorbed dose corresponds to the absorbed NOEL
dose and considering the oral absorption rate determined
in Bouchard et al. [9,10]; 2) a bolus ingestion of one third
of the NOEL at each of the 3 meals per day (7 a.m., noon,
and 6 p.m.); 3) an 8-h dermal exposure starting at 7 am,
that is at time t = 12 h preceding the onset of the nighttime
urine collection period, such that the total absorbed daily
dose corresponds to the absorbed NOEL dose and consid-
ering the dermal absorption rate reported in Bouchard et
al. [9,10].
It is to be noted that the inhibition of RBC-AChE activity
has been used in this report to assess NOEL-biomarker
equivalents given that it has been reported as the reference
biomarker of early cholinergic effect resulting from OP
exposure [34-36]. The use of the NOEL for malathion
reported by Moeller and Rider [32] is currently supported
by Health Canada and that of chlorpyrifos reported by
Coulston et al. (1972) is justified by the review of Zhao et
al. (2006) on the reference dose for chlorpyrifos.
The proposed approach for the assessment of health risks
was also compared to that of Fenske et al. [26], which con-
sists of estimating, with a simple non-modeling approach,
the absorbed daily doses of malathion and CPF from MP
and EP biological measurements, respectively, and com-
paring these reconstructed doses to the WHO's ADI for
these pesticides. The equations used from Fenske et al.
[26] for the estimation of reconstructed doses are pre-
sented below:
dd = []creat. × MW × DCER/BW (1)
or
dd = [] × MW × DUER/BW (2)
where:
dd = Daily dose of the parent OP (malathion or CPF, in
μg/kg-day)
[]creat. = Creatinine-adjusted urinary concentration of MP
or EP, depending on the parent OP (μmol/g of creatinine)
[] = Urinary concentration of MP or EP, depending on the
parent OP (in μmol/L)
MW = Molecular weight of the parent OP (malathion or
CPF, in g/mol)
DCER = Daily creatinine excretion rate (g/day)
DUER = Daily urine excretion rate (L/day)
BW = Body weight (kg)
Results
Table 1 presents the distribution of measured amounts of
MP and EP metabolites in complete first morning voids.
Table 2 presents the NBEs obtained with the model for
MP and EP in 12-h nighttime collections, considering dif-
ferent daily exposure scenarios that may occur in children.
Given that ingestion of OP residues in foodstuffs generally
appears as the main exposure route in children, oral NBEs
for MP and EP metabolites were proposed on the basis of
two different ingestion scenarios. NBEs of 106 and 127
nmol/kg BW for MP in 12-h nighttime collections were
obtained when respectively considering i) an oral expo-
sure to the NOEL of malathion at dinner or ii) an oral
exposure to one third of the NOEL at each of the three
daily meals (breakfast, lunch, dinner). With the same oral
exposure scenarios, a CPF ingestion leads to correspond-
ing NBEs for EP metabolites in 12-h nighttime collections
of 87 and 52 nmol/kg BW. Considering that some OP
exposures in children may also occur through the dermal
Table 1: Distribution of nighttime cumulative amounts of MP and EP metabolites of organophosphorus pesticides measured in the 
urine of children
Metabolite Total amounts in nighttime collections (nmol/kg body weight)a
Geometric mean Minimum Maximum Percentiles
5 2 55 07 5 9 5
Methylphosphates 2.05 0.006 75.4 0.201 0.849 2.10 5.12 15.8
Ethylphosphates 0.233 0.004 7.34 0.031 0.114 0.241 0.547 1.37
Methyl + ethylphosphates 2.43 0.011 77.0 0.306 1.09 2.39 5.66 17.3
Note: Methyl phosphates = the sum of dimethyl dithiophosphates (DMDTP), dimethyl thiophosphates (DMTP) and dimethyl phosphates (DMP); 
ethyl phosphates = the sum of diethyl dithiophosphates (DEDTP), diethyl thiophosphates (DETP) and diethyl phosphates (DEP).
a Incomplete urine voids were excluded.Environmental Health 2009, 8:5 http://www.ehjournal.net/content/8/1/5
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route, dermal NBEs for MP and EP metabolites were also
proposed for comparison purposes. When simulating an
8-h dermal exposure to the NOEL starting at time t = 12 h
preceding the onset of urine collection, the malathion
model from Bouchard et al. [9] yields a NBE of 40 nmol/
kg BW for MP metabolites in 12-h nighttime urine collec-
tions. On the other hand, with the CPF model of Bou-
chard et al. [10], the same dermal exposure scenario leads
to a NBE of 32 nmol/kg BW for EP metabolites in 12-h
nighttime urine collections. Using a sensitivity analysis, it
was however shown in Bouchard et al. [10] that a NBE
based on a 12-h urine collection following the onset of a
dermal exposure scenario is sensitive to the highly varia-
ble dermal absorption rate of CPF whereas a NBE based
on a 12-h urine collection following an oral scenario is
much less affected by variations in the oral absorption
rate.
Table 3 presents the risk estimates obtained when com-
paring the measured amounts of MP and EP metabolites
in urine with the proposed NBEs. These risk estimates cor-
respond to the measured amounts of MP or EP metabo-
lites in each urine sample divided by the proposed NBE
for each of these metabolites. Given that some OP pesti-
cides form MP metabolites while others are metabolized
to EPs, risk estimates obtained on the basis of MP and EP
measurements were also summed to evaluate the effects of
combined exposures to MP and EP generating OPs. Risk
estimates based on MP measurements were greater than
those based on EP measurements, which is expected given
that exposure to MP-generating OPs was on average nine
times greater than exposure to EP-generating pesticides
(Table 1). Table 3 shows that comparison of the observed
amounts of MP and EP metabolites in each of the 442 pro-
vided urine samples with the proposed oral or dermal
NBEs translates into risk estimates lower than 1 in all cases
Table 2: NBEs for MP and EP in urine derived from model simulations of an exposure to a NOEL under different scenarios likely to 
occur in children
Exposure scenario used to derive the NBEs Proposed NBE for methylphosphates in 12-h 
nighttime urine collectionsa
(nmol/kg bw)
Proposed NBE for ethylphosphates in 12-h 
nighttime urine collectionsb
(nmol/kg bw)
Ingestion of a bolus NOEL at dinnerc 106 87
Ingestion of 1/3 NOEL at each meald 127 52
8-h Dermal exposure to the NOELe 40 32
a Corresponds to the total amounts of methylphosphate metabolites in 12-h nighttime collections (from 7:00 pm to 7:00 am) following different 
simulated NOEL exposure scenarios.
b Corresponds to the total amounts of ethylphosphate metabolites in 12-h nighttime collections (from 7:00 pm to 7:00 am) following different 
simulated NOEL exposure scenarios.
c Simulation of an oral exposure to the NOEL of either malathion or chlorpyrifos at 6:00 pm.
d Simulation of an oral exposure to 1/3 of the NOEL of either malathion or chlorpyrifos at 7:00 am, noon and 6:00 pm.
e Simulation of an 8-h dermal exposure to the NOEL of either malathion or chlorpyrifos starting 12 h prior to the onset of urine sampling.
Table 3: Risk estimates based on the comparison of observed MP and EP excretions with the different proposed NBEs
Scenario Risk estimatea No. of risk estimates >1
Metabolites considered mean SD median max
1- Comparison with the oral NBE derived from scenario 1b
Methylphosphates 0.04 0.06 0.02 0.71 0
Ethylphosphates 0.01 0.01 0.01 0.08 0
Sum of methyl+ethylphosphates 0.05 0.07 0.03 0.74 0
2- Comparison with the oral NBE derived from scenario 2c
Methylphosphates 0.04 0.05 0.02 0.59 0
Ethylphosphates 0.01 0.01 0.01 0.14 0
Sum of methyl+ethylphosphates 0.04 0.06 0.02 0.63 0
3- Comparison with the dermal NBEd
Methylphosphates 0.11 0.17 0.05 1.88 1
Ethylphosphates 0.02 0.03 0.01 0.23 0
Sum of methyl+ethylphosphates 0.12 0.17 0.06 1.92 1
a The risk estimate corresponds to the ratio observed metabolite excretion/NBE.
b Simulation of an oral exposure to the NOEL of either malathion or chlorpyrifos at 6:00 pm.
c Simulation of an oral exposure to 1/3 of the NOEL of either malathion or chlorpyrifos at 7:00 am, noon and 6:00 pm.
d Simulation of an 8-h dermal exposure to the NOEL of either malathion or chlorpyrifos starting 12 h prior to the onset of urine sampling.Environmental Health 2009, 8:5 http://www.ehjournal.net/content/8/1/5
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expect one, i.e. when comparing the measured MP value
in one child with the dermal NBE for MP. In this one case,
the MP-based risk estimate approaches the value of 2; con-
sequently, this child was the only one to show a combined
MP and EP risk estimate greater than 1.
Overall, mean risk estimates based on a comparison with
the dermal NBE for MP and EP metabolites or the sum of
MP and EP metabolites were lower than 0.2. When the
comparison was made with an oral NBE, the highest mean
risk estimate was 0.05, the maximum risk value was 0.74
and standard deviations were small indicating that the dif-
ferent individual risk estimate values were generally low.
Table 4 shows that risk estimates in the children under
study were different when the approach followed by Fen-
ske et al. [26] was used, in particular with regard to esti-
mations based on MP measurements. With the approach
of Fenske et al. [26], 130 out of the 442 individual risk
estimates based on absorbed doses reconstructed from
creatinine-adjusted MP concentrations were greater than
1, with a highest risk estimate of 29. When reconstructing
the absorbed doses from volume-weighted MP concentra-
tions, the numbers of individual risk estimates greater
than 1 dropped to 22, with a highest risk estimate of 7.5.
The individual risk estimates based on EP excretions were
much lower. No individual risk estimate calculated from
creatinine-adjusted EP concentrations was greater than 1
(max = 0.8); two of those calculated from volume-
weighted concentrations were greater than 1 (max = 1.6).
Discussion
This work used toxicokinetic models elaborated by Bou-
chard et al. [9,10] to describe the time-courses of
malathion and CPF in humans in order to determine
NOEL-biomarker equivalents (NBEs) under different oral
or dermal exposure scenarios. It mainly contributed to
provide biological reference values to help interpret bio-
monitoring data in order to facilitate public health deci-
sion-making related to the management of OP exposures
in the general environment rather than in occupational
settings as was done in the past [9,10].
Oral NBEs for MP and EP excretions based on two differ-
ent exposure scenarios were determined in the present
work along with a dermal NBE for MPs and EPs. The oral
NBEs for MP and EP excretions are less conservative than
the dermal NBE. The lower dermal NBE values result from
the lower dermal absorption rate of malathion and CPF
compared to the oral absorption rate [8,10], which trans-
lates into lower amounts of MP or EP metabolites in 0–12
or 0–24 h collections following the onset of an 8-h dermal
exposure to the NOEL as compared to a bolus oral expo-
sure. Given these kinetic considerations, the lowest oral
NBE should provide a safe biological reference value
below which the risk of cholinergic effects should be neg-
ligible in the general population, when exposure is most
likely due mainly to the ingestion of OP residues on food.
When the exposure scenario is not known or a dermal
exposure is suspected, the use of the dermal NBE as a bio-
logical reference value corresponds to the more conserva-
tive approach, ensuring a certain margin of safety in the
risk estimate.
The proposed biological reference values for MP and EP
metabolites are based on the available models for
malathion and chlorpyrifos. These models were devel-
oped with a given set of data and validated with a different
set of data in orally and dermally exposed human volun-
teers. A good approximation of the experimental data was
obtained in all cases ensuring the robustness of the mod-
els as detailed in Bouchard et al. [9,10]. Models for azin-
phos-methyl and parathion were also available, which
allowed links to be made between an exposure or
absorbed dose and MP or EP biomarker measurements,
respectively. The reported human NOEL for azinphos-
Table 4: Risk estimates based on comparisons of reconstructed absorbed dose of malathion and chlorpyrifos with WHO's ADI
Scenario Risk estimatea No. of risk estimates >1
Metabolites considered mean SD median max
1- Comparison of the dose, reconstructed from creatinine-adjusted 
concentrations, with the ADI
Methylphosphates 1.10 2.18 0.51 29.1 130
Ethylphosphates 0.05 0.08 0.03 0.8 0
Sum of methyl + ethylphosphates 1.18 2.21 0.55 29.4 139
2- Comparison of the dose, reconstructed from volume-weighted 
concentrations, with the ADI
Methylphosphates 0.30 0.55 0.13 7.5 22
Ethylphosphates 0.07 0.13 0.04 1.6 2
Sum of methyl + ethylphosphates 0.36 0.61 0.19 7.8 33
a The risk estimate corresponds to the ratio of calculated dose, reconstructed from methyl and ethyl phosphate urinary excretion, divided by 
WHO's ADI.Environmental Health 2009, 8:5 http://www.ehjournal.net/content/8/1/5
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methyl (0.29 mg/kg/d) and parathion (0.058 mg/kg/d) is
similar to that of malathion and chlorpyrifos (0.2 and 0.1
mg/kg/d, respectively) [8-11]. With the model for azin-
phos-methyl, the MP biomarker levels corresponding to
the NOEL for this OP provided biological reference values
slightly higher albeit in the same range (154, 139, 63
nmol/kg BW) as the ones obtained using the model for
malathion (106, 127, 40 nmol/kg BW). The slightly
higher biological reference values for azinphos-methyl
despite a slightly lower NOEL are related to variations in
the toxicokinetics of the two substances. As for the model
for parathion, it was considered less appropriate than the
model for CPF for modeling EP biomarker levels given
that there appears to be a delay in the renal excretion of EP
metabolites of parathion presumably due to para-nitro-
phenol metabolites of this OP [11,33].
Obviously, the children under study could theoretically
have been exposed to other potentially more toxic OP pes-
ticides than malathion and chlorpyrifos. However,
according to the last survey on estimated average daily
intakes of pesticide residues in Canadians [37],
malathion, azinphos-methyl, chlorpyrifos, methylpar-
athion, phosmet and phosalone were the OP pesticides to
which the general population was mostly exposed
through the diet. More recent unpublished data, collected
at the time the children under study were sampled, tend
to confirm this trend [38]. For methylparathion, phosmet
and phosalone, no toxicokinetic model are yet available,
but a human NOEL of 0.3 mg/kg/d has been reported for
methylparathion, similar to that of malathion and azin-
phos-methyl, and a rat NOEL of 0.2 and 2 mg/kg/d was
established for phosalone and phosmet, respectively [39].
As a result, an important contribution of significantly
more toxic OP pesticides to the measured AP metabolites
in the children under study appears unlikely.
Nonetheless, the children under study may have been
exposed concurrently to several OPs by different routes
(although oral exposure is the most likely route-of-entry).
To account for possible multiple exposure routes, the
more conservative NBE resulting from the dermal expo-
sure scenario can thus be used, as mentioned earlier. Con-
comitant exposure to several OP pesticides was also
accounted for in our evaluation since EP and MP metabo-
lites are non-specific OP metabolites and thus respectively
result from the biotransformation of all EP and MP-pro-
ducing OP pesticides. Calculating risk estimates from the
sum of EP and MP metabolites rather than MP alone did
not result in an increased number of values greater than 1.
It was also found from model simulations that the deriva-
tion of NBEs considering a single daily exposure rather
than a repeated daily exposure also contributes to provide
safer NBE estimates. This is explained by the increase in
daily urinary excretion of MP and EP metabolites,
expressed as a fraction of the absorbed daily dose, during
a repeated daily exposure, as can be shown from model
simulations.
It is to be noted that the present study proposes biological
reference values for non-specific metabolites of OP pesti-
cides measured in urine. Estimating the risk resulting from
an exposure to a given pesticide based on urinary meas-
urements of specific metabolites is generally more accu-
rate in the case of occupational exposure where the
pesticide involved can be easily identified. Conversely, the
proposal of biological reference values for non-specific
OP metabolites rather than specific metabolites appears
more accurate for environmental risk assessment of OP
exposure where the pesticides to which subjects are
exposed are unknown. Although some of the measured
non-specific metabolites could stem from environmental
degradation products already present in food [40], this
would result in an actual overestimation of the human
exposure to the parent compounds and thus of the human
health risks. Indeed, toxicological activity of OP pesticides
results from the oxon metabolite generated by the break-
down of the parent compounds, and the AP metabolites
that are produced as by-products do not have toxicologi-
cal activity.
With the derived NBEs, the toxicological risks attributed
to OP exposures in a group of children were assessed
using MP and EP measurements in several first-morning
urine voids. On the basis of our approach, that is the com-
parison of the observed excretion values of MP and EP
metabolites in children with the proposed NBEs, the chil-
dren under study should incur a negligible risk of cholin-
ergic effects related to OP pesticide exposure. Indeed, only
one sample presented a risk estimate greater than 1 (1.88
on the basis of MP excretion and 1.92 on the basis of MP
+ EP excretion, when compared to a dermal NBE). In com-
parison, the results obtained by using the method of Fen-
ske et al. [26] generated more concerning results (see
Table 4). However, their method consists of comparing a
calculated biologically-based dose estimates with the ADI
used at the time [39]. In the case of malathion and CPF,
the ADI is based on a human NOEL (0.2 and 0.1 mg/kg/
d, respectively) to which a 10-fold uncertainty factor was
applied to account for inter-individual variations within a
population [39]. In our study, when considering MP-
based risk estimates, a difference of approximately one
order of magnitude was found between the risk estimates
obtained with the NOEL-biomarker equivalent approach
and those calculated from the comparison of an estimated
absorbed dose of malathion and CPF and their ADI. This
difference of one order of magnitude in risk values
between the two approaches may stem from the use of a
10-fold uncertainty factor for interindividual variationsEnvironmental Health 2009, 8:5 http://www.ehjournal.net/content/8/1/5
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when establishing the ADI for malathion. Indeed, the tox-
icokinetic models used to obtain the NBEs were elabo-
rated and validated with human data and the human
NOELs used in model simulations were the same as those
considered for the derivation of the ADI; however, no
uncertainty factor for interindividual variations was intro-
duced with our kinetic approach.
The NBEs for cholinergic effects are still proposed with a
margin of safety since the NOEL used to derive biomarker
equivalents were based on the inhibition of red blood cell
acetylcholinesterases (AChEs); these AChEs are more sen-
sitive to OP inhibition than nervous system AChEs [41],
responsible for the neurotoxic effects of OPs. The pro-
posed NBEs were also based on a NOEL instead of a low-
est-observed effect level (LOEL) [8,10]. Thus, an exposure
exceeding a NOEL-based reference value does not imply
that it exceeds the minimum dose required to produce an
adverse effect. In our analysis of the studied children,
since only one out of the 442 risk estimates exceeded the
value of 1 and did not reach the value of 2, it appears
unlikely that the exposure doses in the children under
study exceeded the LOEL dose. Indeed, Dourson et al. [42]
evaluated that the difference between a LOEL and a NOEL
is at least two-fold 75% of the time.
Uncertainties in our NBE estimates are nevertheless
related to the fact that the models used to develop our
NBEs were elaborated using data in adults rather than in
children. Although children are generally considered
potentially more exposed to pesticides than adults, partly
due to their specific behaviors (hand-to-mouth behavior,
crawling) and physiological characteristics (higher dermal
permeability) [43,44], for a given molar absorbed dose
per unit of body weight, evidence that children of the age
group under study (3–7 years old) are more sensitive than
adults, on a toxicodynamic basis, remains to be con-
firmed. On the other hand, this does not preclude the pos-
sibility of kinetic differences between children and adults
[45]. Interindividual variations in the inhibition capacity
are also to be expected. If a default uncertainty factor of 10
was added to account for inter-individual variability or
potential kinetic or sensitivity differences between adults
and children, 138, 45 and 35 out of the 442 samples col-
lected would respectively present MP values exceeding the
reference value for the dermal exposure scenario and the
two oral scenarios. In the case of EPs, corresponding val-
ues would be 5, 3 and 0. These values are similar to those
obtained using the method of Fenske et al. [26]. However,
Zhao et al. [36] reported that the necessity of applying this
factor has to be put into perspective since the results of
Mattsson et al. [46] unequivocally show that neonatal and
young animals are equally or perhaps less sensitive than
adults to ChE inhibition on a tissue dose and tissue
response specific basis. Also, from the results of the study
of Zheng et al. [47], it appears that neonatal experimental
animals are not more sensitive than adults to repeated
exposure to chlorpyrifos. In any case, Zhao et al. [36]
stated in their review that an uncertainty factor of 10 was
deemed sufficient to account for the overall uncertainty in
the fairly large database used to assess a reference dose for
chlorpyrifos.
In the models for malathion and chlorpyrifos, there is also
an uncertainty in the fraction of the exposure dose consid-
ered to be recovered in the urine as MP or EP metabolites,
when applied to a large group of children. A lower fraction
than the one used in the model would have generated
more conservative NBEs, hence with a direct impact on
the number of studied children with AP excretions exceed-
ing the biological reference values.
Other uncertainties are linked to the fact that acetylcho-
linesterase inhibition was considered the critical effect
although effects appearing at lower doses, such as neu-
robehavioral effects [48,49], cannot be excluded. In par-
ticular, Grandjean et al. [31] reported an increased
reaction time after a visual and auditory stimulus in chil-
dren exposed to OP levels that were not associated with an
inhibition acetylcholinesterase activities in red blood
cells. The urinary levels measured in the children evalu-
ated in the current study [22] were 5–6 times greater than
those measured by Eskenazi et al. [49] in children for
which developmental effects were reported to be posi-
tively associated with urinary AP metabolites, although
with limited evidence.
It should also be noted that the risk of OP exposure was
characterized in the current study from complete single
urine voids, which are easy to obtain. A 24-h urine collec-
tion, although less practical, would have been a better
sampling strategy given the large influence of the absorp-
tion rate on excretion during the first hours following an
exposure [9,10]. Therefore, it cannot be excluded that the
pattern of risk estimates might have been different, on the
basis of 24-h urine collections.
Conclusion
In conclusion, observed MP and EP excretions in children
were compared with NOEL-biomarker equivalents deter-
mined using published toxicokinetic models. This toxico-
logical approach indicated that the children under study
generally exhibited biological OP levels below the derived
NBEs. The proposed oral and dermal biological reference
values for MP and EP excretions can be used to help inter-
pret biomonitoring data in other populations where
nighttime cumulative urinary excretions are collected.Environmental Health 2009, 8:5 http://www.ehjournal.net/content/8/1/5
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